Ozempic vs Mounjaro: Semaglutide vs Tirzepatide for Type 2 Diabetes

Ozempic (semaglutide) and Mounjaro (tirzepatide) are both once-weekly injectable medications approved for type 2 diabetes, but they work through different mechanisms and the trial data shows meaningful differences in both glucose control and weight loss. This comparison breaks down what the evidence says so you can have a more informed conversation with your prescriber.

Quick Reference: Ozempic vs Mounjaro

• Ozempic is a GLP-1 receptor agonist (single hormone). Mounjaro is a dual GIP/GLP-1 receptor agonist (two hormones).
• In the head-to-head SURPASS-2 trial, Mounjaro produced greater A1C reductions at all doses compared to Ozempic 1 mg.
• Weight loss with Mounjaro 15 mg averaged 12.4 kg vs 6.2 kg with Ozempic 1 mg over 40 weeks.
• Both are once-weekly SubQ injections with similar GI side effect profiles.
• Mounjaro is made by Eli Lilly; Ozempic is made by Novo Nordisk.

Comparison Table

How the Mechanisms Differ

Understanding why these medications produce different results starts with their receptor targets.

Ozempic activates the GLP-1 receptor exclusively. When GLP-1 receptors are stimulated, your pancreas increases insulin secretion in response to elevated blood glucose, your liver reduces glucose output, gastric emptying slows, and appetite centers in the hypothalamus receive satiety signals. This is the same pathway that natural GLP-1 (released by your gut after eating) uses — semaglutide just sustains the signal for a full week instead of minutes.

Mounjaro activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. It enhances glucose-dependent insulin secretion through a separate pathway, improves insulin sensitivity in peripheral tissues, and appears to influence lipid metabolism and fat storage. In preclinical models, GIP receptor activation also showed effects on energy expenditure.

The dual mechanism is not just additive. Tirzepatide's molecular structure is based on the GIP sequence with modifications that allow GLP-1 receptor binding. It has roughly five-fold higher affinity for the GIP receptor than the GLP-1 receptor. This means Mounjaro leans more heavily on GIP signaling than most people assume — it is not simply "Ozempic plus a second hormone."

Clinical Trial Results

The SURPASS-2 Head-to-Head

SURPASS-2 is the most directly relevant trial because it compared tirzepatide against semaglutide in the same study. Published in the New England Journal of Medicine in 2021, this 40-week trial enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin.

A1C reductions:

• Tirzepatide 5 mg: -2.01%
• Tirzepatide 10 mg: -2.24%
• Tirzepatide 15 mg: -2.30%
• Semaglutide 1 mg: -1.86%

All three tirzepatide doses were statistically non-inferior to semaglutide 1 mg. The 10 mg and 15 mg doses were statistically superior.

Weight loss:

• Tirzepatide 5 mg: -7.6 kg
• Tirzepatide 10 mg: -9.3 kg
• Tirzepatide 15 mg: -12.4 kg
• Semaglutide 1 mg: -6.2 kg

An important caveat: the comparator was semaglutide 1 mg, not the 2 mg dose that was approved later. The 2 mg dose produces somewhat greater A1C reduction and weight loss than 1 mg, so the gap between maximum-dose Ozempic and Mounjaro may be narrower than SURPASS-2 suggests — though still likely favors tirzepatide based on the dose-response curves.

SUSTAIN Program (Semaglutide)

The SUSTAIN trials established semaglutide's efficacy across multiple comparators. Key results:

• SUSTAIN-1 (vs placebo): A1C reduction of -1.55% at 0.5 mg, -1.80% at 1 mg
• SUSTAIN-6 (cardiovascular outcomes): 26% reduction in major adverse cardiovascular events (MACE) vs placebo
• SUSTAIN-7 (vs dulaglutide): Semaglutide 1 mg produced -1.8% A1C reduction vs -1.4% for dulaglutide 1.5 mg

SURPASS Program (Tirzepatide)

• SURPASS-1 (vs placebo): A1C reduction up to -2.07% at 15 mg, with 25% of participants achieving normal A1C (<5.7%)
• SURPASS-3 (vs insulin degludec): Tirzepatide produced greater A1C reduction with weight loss vs weight gain with insulin
• SURPASS-4 (vs insulin glargine, high CV risk): Non-inferior A1C reduction with significant weight advantage

Dosing Comparison

Both medications use a slow titration approach to reduce GI side effects, but the schedules differ.

Ozempic titration:

1. 0.25 mg weekly for 4 weeks (initiation dose, not therapeutic)
2. 0.5 mg weekly for at least 4 weeks
3. 1 mg weekly (can remain here)
4. 2 mg weekly (if additional glycemic control needed)

Total time to max dose: minimum 12 weeks.

Mounjaro titration:

1. 2.5 mg weekly for 4 weeks (initiation dose)
2. 5 mg weekly for at least 4 weeks
3. 7.5 mg weekly for at least 4 weeks
4. 10 mg weekly for at least 4 weeks
5. 12.5 mg weekly for at least 4 weeks
6. 15 mg weekly (maximum dose)

Total time to max dose: minimum 24 weeks.

Mounjaro has more granular dose steps, which gives prescribers more flexibility to find a dose that balances efficacy with tolerability. This is particularly relevant for patients who experience significant GI symptoms — you can park at an intermediate dose (like 7.5 or 10 mg) without jumping to the maximum.

Both medications are administered SubQ using prefilled auto-injector pens. Neither requires reconstitution. Injection sites include the abdomen, thigh, and upper arm. You can inject on any day of the week, as long as doses are at least 3 days (72 hours) apart if you change your injection day.

Side Effects Comparison

The GI side effect profiles overlap significantly, which makes sense given that both activate GLP-1 receptors. However, there are some differences in the data.

Nausea was the most commonly reported adverse event for both medications. In SURPASS-2, nausea rates ranged from 17% to 23% across tirzepatide doses vs 18% for semaglutide 1 mg. Nausea typically peaks during dose escalation and subsides after 4-8 weeks at a stable dose.

Diarrhea was more common with tirzepatide (12-17%) than semaglutide (9%) in SURPASS-2. This is consistent across the SURPASS program and may relate to GIP receptor activation's effects on intestinal motility.

Vomiting was roughly comparable: 6-9% with tirzepatide vs 8% with semaglutide.

Decreased appetite was reported more frequently with tirzepatide at higher doses, which aligns with the greater weight loss observed.

Injection site reactions are uncommon with both but occur slightly more often with tirzepatide pens. These are typically mild redness or itching that resolves within a day.

Serious adverse events were rare in both groups. Both medications carry boxed warnings about medullary thyroid carcinoma risk based on rodent studies, and both are contraindicated in patients with personal or family history of MTC or MEN2.

Neither medication should be combined with other GLP-1 receptor agonists. Both can be used alongside metformin, SGLT2 inhibitors, and basal insulin (with appropriate dose adjustments to avoid hypoglycemia).

Cardiovascular Data

This is where Ozempic currently has a significant advantage. The SUSTAIN-6 trial and the larger SELECT trial demonstrated cardiovascular benefits for semaglutide — including a 20% reduction in MACE in the SELECT trial (which studied semaglutide 2.4 mg in patients with established cardiovascular disease and obesity). Mounjaro's dedicated cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing. Until it reports, tirzepatide lacks the same level of cardiovascular evidence.

Practical Tracking Considerations

Both medications are once-weekly injections, which simplifies adherence compared to daily medications. But "once a week" still leaves room for error — especially when you're titrating doses, managing side effects, or coordinating with other medications.

What to track with either medication:

• Injection date, time, and dose
• Injection site (rotate between abdomen, thigh, and upper arm)
• GI symptoms and severity (especially during titration)
• Weight (weekly, same conditions — morning, fasted, same scale)
• Fasting blood glucose or CGM data if available
• A1C at each lab draw
• Missed doses and how they were handled

Why tracking matters more during the switch: If you're transitioning from Ozempic to Mounjaro (or vice versa), your body is adjusting to a different receptor activation profile. Tracking symptoms during the transition gives you and your clinician real data to guide dose decisions instead of relying on memory.

Which Is Right for You

There is no universal "better" medication here. The choice depends on several factors:

Mounjaro may be preferred when:

• Maximum A1C reduction is the primary goal
• Significant weight loss is desired alongside glycemic control
• You've plateaued on Ozempic and want to try a different mechanism
• You prefer more granular dose titration options

Ozempic may be preferred when:

• Cardiovascular risk reduction is a priority (established CV outcome data)
• You're already well-controlled on semaglutide and tolerating it
• Insurance coverage or formulary placement favors it
• Your prescriber has more experience managing patients on semaglutide

Neither medication is appropriate if:

• You have personal or family history of medullary thyroid carcinoma or MEN2
• You have a history of pancreatitis (relative contraindication — discuss with your prescriber)
• You are pregnant, planning pregnancy, or breastfeeding

The decision is always a conversation between you and your prescribing clinician. Bring your tracking data — dose history, side effect patterns, weight trends, and lab results — to make that conversation as productive as possible.

Frequently Asked Questions

Is Mounjaro better than Ozempic for type 2 diabetes?

In the head-to-head SURPASS-2 trial, tirzepatide (Mounjaro) at all three doses produced greater A1C reductions and more weight loss than semaglutide 1 mg (Ozempic). However, "better" depends on your specific clinical situation, tolerability, insurance coverage, and prescriber recommendation.

Can you switch from Ozempic to Mounjaro?

Yes, switching is common and clinically straightforward. Your prescriber will typically start you at a lower Mounjaro dose (2.5 mg) regardless of your Ozempic dose, then titrate up. There is no required washout period between the two medications.

Do Ozempic and Mounjaro have the same side effects?

The side effect profiles are similar — both primarily cause GI symptoms like nausea, diarrhea, vomiting, and constipation. Rates in clinical trials were comparable, though tirzepatide showed slightly higher rates of diarrhea and slightly lower rates of nausea at equivalent efficacy doses.

Which is cheaper, Ozempic or Mounjaro?

List prices are similar (roughly $900-1,100/month without insurance as of early 2026), but actual out-of-pocket cost depends entirely on your insurance plan, tier placement, and available manufacturer savings programs. Check both manufacturers' patient assistance programs.

Sources

1. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
2. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
3. Pratley RE, et al. Semaglutide versus Dulaglutide in Type 2 Diabetes. Lancet Diabetes Endocrinol. 2018;6(4):275-286. doi:10.1016/S2213-8587(18)30024-X
4. Rosenstock J, et al. Tirzepatide for the Treatment of Type 2 Diabetes (SURPASS-1). N Engl J Med. 2021. doi:10.1056/NEJMoa2032183

Tracking your medication — whether it's Ozempic, Mounjaro, or both during a transition — is one of the most practical things you can do to stay on top of your treatment. DoneDose helps you log every injection, track side effects, and keep your dose history organized for your next prescriber visit.